Visium Asset Management Adds NephroGenex Inc (NRX) and Ignyta Inc (RXDX) to its Equity Portfolio

Visium Asset Management, led by Jacob Gottlieb, has added NephroGenex Inc (NASDAQ:NRX) and Ignyta Inc (OTCBB:RXDX) to its equity portfolio. According to a filing with the Securities and Exchange Commission, Jacob Gottlieb’s fund holds around 476,491 shares of NephroGenex, the passive stake amassing 5.4% of the common stock.


NephroGenex Inc (NASDAQ:NRX) is a drug development company that focuses on novel therapies for kidney disease. The company went public last week, issuing 3.1 million shares at a price of $12 apiece. A 45-day option to purchase an additional amount of 465,000 shares has also been granted to the underwriters.

Last week, directors R. Robert Seltzer, Richard Markham and Llc Iii Capital Care, each purchased 790,000 shares of NephroGenex Inc (NASDAQ:NRX) and now own 4.24 million shares individually.

In the second filing, Visium Asset Management reported ownership of 833,300 shares of Ignyta Inc (OTCBB:RXDX). Currently the position amasses around 6.2% of the company’s common stock.

In the fourth quarter of last year, Visium Asset Management, revealed boosting its position in Zogenix, Inc. (NASDAQ:ZGNX) to 8.9 million shares, from 1.7 million held at the end of the previous quarter, the fund revealed owning 9.11 million shares of Zogenix, Inc. at the end of the fourth quarter. Jacob Gottlieb also upped its stake in QLT Inc. (USA) (NASDAQ:QLTI) to 3.5 million shares, from 2.0 million shares held earlier.

Allergan, Inc. (NYSE:AGN), stands on the first spot in Jacob Gottlieb’s equity portfolio, where the fund has invested 5.77% of its equity portfolio amassing 2.65 million shares. The fund also initiated a position in Watson Pharmaceuticals Inc (WPI) in the fourth quarter and now owns 1.46 million shares, worth $245.69 million.

Disclosure: none

Recommended Reading:

Corvex Capital Exercises Options and Reiterates Stake in Signet Jewelers Limited (SIG)

Carl Wiese’s Grow Partners Top Picks in Q4

York Capital Management’s Top Q4 Holdings

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!